Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Prevention of acute radiodermatitis by photobiomodulation: preliminary results of a randomized, placebo-controlled trial in breast cancer patients|
|Authors: ||Robijns, Jolien|
|Issue Date: ||2017|
|Citation: ||37th Annual Conference of the American Society for Laser Medicine and Surgery (ASLMS 2017), San Diego, USA, 07-09/04/2017|
The aim is to evaluate the effectiveness of photobiomodulation therapy (PBMT) in the prevention
of acute radiodermatitis (RD) in breast cancer patients undergoing radiotherapy (RT).
Study Design/Materials and Method
This randomized, placebo-controlled trial enrolled 66 breast cancer patients that underwent an
identical RT regime post-lumpectomy. Patients were randomly assigned to the laser (n=34) or
placebo group (n=32). There were no significant differences between the two groups with respect
to patient- and treatment-related characteristics. Laser or placebo was applied two days a week,
immediately after the RT session, starting at the first day of RT. PBMT was delivered using a class
IV MLS® M6 laser that combines two synchronized laser diodes in the infrared range (808-905 nm)
with a fixed energy density (4 J/cm2). Clinical scoring of RD (Radiation Therapy Oncology Group
(RTOG) grading scale) and biophysical measurements (skin hydration, transepidermal water loss
(TEWL), and degree of erythema) were determined at the first day, at fraction 20 and at the end
of RT. In the results section, only preliminary results of the RTOG scores are shown.
At fraction 20 of RT, there was no significant difference between the groups in the distribution of
RTOG grades (p= .524), with most of the patients presenting RTOG grade 1. Towards the end of
RT, the skin reactions worsened in the placebo group (p= 0.016), while they remained stable in
the laser group (p= .207). There was a significant difference in the severity of RD between the two
groups (p= .021) with a larger percentage of patients experiencing RTOG grade 2 or higher (e.g.
moist desquamation) in the placebo group (28.1% vs. 5.9%, for the placebo and laser group,
resp.) at the last day of RT.
The preliminary results of this first randomized, placebo-controlled trial show that PBMT can
prevent aggravation of acute RD in breast cancer patients.|
|Type: ||Conference Material|
|Appears in Collections: ||Research publications|
Files in This Item:
|N/A||525.14 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.